| HIV Infections
Stribild vs Truvada
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Stribild vs Truvada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTruvada has a higher rate of injection site reactions vs Stribild based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Truvada but not Stribild, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Stribild
Truvada
At A Glance
Oral
Once daily
Integrase inhibitor + CYP3A inhibitor + nucleoside/nucleotide analog reverse transcriptase inhibitors
Oral
Once daily
NRTI combination (FTC + TDF)
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections One tablet (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir disoproxil fumarate 300 mg) taken orally once daily with food in adults and pediatric patients 12 years of age and older with body weight at least 35 kg and creatinine clearance >=70 mL/min.
HIV Infections Adults and pediatric patients weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; pediatric patients weighing 17 to <35 kg: weight-based lower-strength tablet (100 mg/150 mg, 133 mg/200 mg, or 167 mg/250 mg) once daily; CrCl 30-49 mL/min: one tablet every 48 hours; CrCl <30 mL/min or hemodialysis: not recommended.
HIV-1 Pre-Exposure Prophylaxis HIV-1 uninfected adults and adolescents weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; not recommended if CrCl <60 mL/min.
Contraindications
- Coadministration with alfuzosin
- Coadministration with carbamazepine, phenobarbital, or phenytoin
- Coadministration with rifampin
- Coadministration with lurasidone or pimozide
- Coadministration with dihydroergotamine, ergotamine, or methylergonovine
- Coadministration with St. John's wort (Hypericum perforatum)
- Coadministration with lomitapide, lovastatin, or simvastatin
- Coadministration with sildenafil when used for pulmonary arterial hypertension
- Coadministration with triazolam or orally administered midazolam
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B in coinfected patients, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Allergic reactions including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, increased amylase, abdominal pain, hepatic steatosis, hepatitis, increased liver enzymes, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, renal failure, acute tubular necrosis, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, renal insufficiency, increased creatinine, proteinuria, polyuria, asthenia
Most common (>=10%) Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash
Serious Severe acute exacerbations of hepatitis B, new onset or worsening renal impairment, immune reconstitution syndrome, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Allergic reaction including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, hepatic steatosis, hepatitis, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, proteinuria, asthenia
Pharmacology
STRIBILD is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor), cobicistat (a CYP3A inhibitor that boosts elvitegravir levels), emtricitabine (a nucleoside reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor).
FTC and TDF are both nucleoside analog reverse transcriptase inhibitors (NRTIs); each is converted intracellularly to an active triphosphate form that inhibits HIV-1 reverse transcriptase by competing with natural dNTP substrates and causing chain termination. No antagonism between FTC and TDF has been observed in cell culture combination studies.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Stribild
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Truvada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Stribild
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (3/8) · Qty limit (5/8)
Truvada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Stribild
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Truvada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
StribildView full Stribild profile
TruvadaView full Truvada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.